[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630072":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":24,"locations":33,"responsibleParty":53,"collaborators":24,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":24,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":79,"overallStatus":35,"whyStopped":24,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Hospital de Granollers","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard ILD Diagnostic Pathway","ACTIVE_COMPARATOR","Participants in this arm will follow the standard ILD diagnostic pathway. After referral for suspected ILD and confirmation of eligibility, core diagnostic procedures-such as high-resolution chest computed tomography, complete pulmonary function tests (spirometry and diffusing capacity), six-minute walk test and a comprehensive ILD laboratory panel-are ordered and scheduled independently according to routine departmental workflows and waiting times. Additional procedures, including bronchoscopy with bronchoalveolar lavage, rheumatology or internal medicine assessment, or lung biopsy when indicated, are requested through usual clinical channels. These tests typically occur on different days. The final ILD diagnosis is assigned once all required results are available and reviewed in the ILD unit or in a multidisciplinary discussion when appropriate. The study team does not modify scheduling priorities, clinical decisions or the type of tests performed.",[13],"Other: Standard ILD Diagnostic Pathway",{"label":15,"type":16,"description":17,"interventionNames":18},"Optimized ILD Diagnostic Circuit","EXPERIMENTAL","Participants in this arm will follow a coordinated ILD diagnostic circuit in which the same core diagnostic procedures-high-resolution chest computed tomography, complete pulmonary function tests with spirometry and diffusing capacity, six-minute walk test and a comprehensive ILD laboratory panel-are pre-bundled and scheduled within a compressed and coordinated timeframe, in as few hospital visits as possible. When clinically indicated, additional evaluations such as bronchoscopy or rheumatology\u002Finternal medicine consultation are integrated into the same coordinated workflow. All available diagnostic information is reviewed in a single multidisciplinary discussion to assign the final ILD diagnosis and initial therapeutic plan. The intervention does not introduce new diagnostic tests, alter clinical content or modify prioritization rules; it reorganizes the timing and coordination of existing diagnostic steps to reduce fragmentation and diagnostic delays.",[19],"Other: Optimized ILD Diagnostic Circuit",[21,25],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"Organizational usual-care comparator following the standard ILD diagnostic workflow. After referral for suspected ILD, core diagnostic procedures such as high-resolution chest computed tomography, complete pulmonary function tests (spirometry and diffusing capacity), six-minute walk test, and a comprehensive ILD laboratory panel are ordered and scheduled independently according to routine departmental workflows and waiting times. Additional procedures, including bronchoscopy with bronchoalveolar lavage or rheumatology\u002Finternal medicine assessment, are requested when clinically indicated. These diagnostic tests and visits usually occur on separate days, and the final diagnosis is assigned once all required results are available and reviewed in the ILD unit or in a multidisciplinary discussion. The intervention does not modify clinical content, scheduling priorities, or the type of tests performed.",[9],null,{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Organizational intervention that coordinates and bundles core ILD diagnostic procedures into a compressed and structured workflow. For patients with suspected ILD, high-resolution chest computed tomography, complete pulmonary function tests (spirometry and diffusing capacity), the six-minute walk test, and a comprehensive ILD laboratory panel are pre-bundled and scheduled within a shortened timeframe, ideally within one or two coordinated visits. When required, bronchoscopy and rheumatology\u002Finternal medicine assessments are integrated into the same coordinated pathway. All available diagnostic results are reviewed in a single multidisciplinary discussion to assign the final ILD diagnosis and the initial therapeutic plan. The intervention does not introduce new tests or alter clinical decision-making; it reorganizes the timing and coordination of existing procedures without modifying waiting-list rules.",[15],[29],{"name":30,"affiliation":31,"role":32},"Jaume Bordas-Martinez, MD, PhD","Hospital General de Granollers","PRINCIPAL_INVESTIGATOR",[34],{"facility":31,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Granollers","Barcelona","08402","Spain","ES",{"type":42,"coordinates":43},"Point",[44,45],2.28773,41.60797,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":51,"phoneExt":24,"email":52},"Jaume Bordas-Martínez, MD, PhD","CONTACT","+34 938 425 000","jbordas@fphag.org",{"type":32,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Jaume Bordas-Martinez","Principal Investigator","100630072","optimizing-the-diagnostic-journey-in-interstitial-lung-disease-the-optimize-ild-1-trial-100630072",false,"NCT07482917","Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial","OPTIMIZE-ILD-1: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Diagnostic Circuit on Time to Diagnosis in Patients With Suspected Interstitial Lung Disease","OPTIMIZE-ILD-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Referral for suspected or undiagnosed interstitial lung disease (ILD).\n* At least one of the following:\n\n  * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or\n  * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel).\n* Established diagnosis of ILD previously assigned by another center or specialist.\n* Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure).\n* Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent.\n* Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection.\n* Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures.\n* Cognitive impairment that prevents informed consent or completion of study questionnaires.\n* Refusal to participate or to allow the collection or use of clinical data.","ALL","18 Years",{"count":67,"type":68},92,"ESTIMATED","INTERVENTIONAL",[71],"NA","The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe.\n\nAll eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent.\n\nThe design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.",[74,75,76,77,78],"Interstitial Lung Disease (ILD)","Suspected Interstitial Lung Disease","Fibrotic Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis (IPF)","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100],"Interstitial Lung Disease","ILD","Suspected ILD","Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Connective Tissue Disease-ILD","IPF","Diagnostic Pathway","Diagnostic Delay","Multidisciplinary Discussion","One-Day ILD Clinic","Time to Diagnosis","Time to Treatment Initiation","Organizational Intervention","Health Services Research","Diagnostic Workflow Optimization","Patient Experience","Quality of Life","Pulmonary Function Tests","High-Resolution CT","Carbon Footprint","2026-06-30",{"date":103,"type":104},"2026-07-02","ACTUAL",{"date":106,"type":104},"2026-03-09",{"date":108,"type":68},"2028-03-01",{"name":5,"class":6},1]